Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novelion Therapeutics Inc (NASDAQ:NVLN)

9.94
Delayed Data
As of Jun 26
 -0.63 / -5.96%
Today’s Change
6.10
Today|||52-Week Range
13.80
+18.05%
Year-to-Date
No recent news for Novelion Therapeutics Inc.

Today’s Trading

Previous close10.57
Today’s open10.40
Day’s range9.93 - 10.68
Volume125,474
Average volume (3 months)112,782
Market cap$196.6M
Dividend yield39.42%
Data as of 3:59pm ET, 06/26/2017

Growth & Valuation

Earnings growth (last year)-113.18%
Earnings growth (this year)+86.37%
Earnings growth (next 5 years)+74.60%
Revenue growth (last year)--
P/E ratioNM
Price/Sales7.00
Price/Book1.44

Competitors

 Today’s
change
Today’s
% change
CDXCChromadex Corp+0.34+9.39%
NATRNatures Sunshine Pro...0.000.00%
CTSOCytosorbents Corp-0.05-1.16%
CDTXCidara Therapeutics ...+0.60+8.96%
Data as of 4:00pm ET, 06/26/2017

Financials

Next reporting dateAugust 9, 2017
EPS forecast (this quarter)-$0.27
Annual revenue (last year)$13.6M
Annual profit (last year)-$52.9M
Net profit margin-389.49%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mary J. Szela
Director, Chief Financial &
Administrative Officer
Gregory D. Perry
Corporate headquarters
Vancouver, British Columbia

Forecasts